BCL2 and ovarian cancer: Finally, in a 4T1 breast cancer study and glioma mouse subcutaneous xenograft study, lipophilic MnP analogs suppressed levels of BCL2 [6, 7], which has been reportedly upregulated in ovarian cancer patients [34, 35].